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the first study. Guess [10] found that 20 in 100000 children
under the age of 5 fall ill, and 63 in 100 000 ofpersons between
the ages of 15 and 19. Herpes zoster was significantly more
frequent in children with acute lymphocytic leukemia. Accord-
ing to the data from this study, the risk factor for childhood
herpes zoster was chickenpox before the first year of age.
Another study [11], which was conducted a few years ago,
reported an even higher incidence ofherpes zoster; it affects 160
in 100 000 persons younger than 19. Herpes zoster most
frequently appeared in the thoracic region. The course of
the disease was mainly mild, and none of the patients had
post-herpetic neuralgia. A significantly higher number of com-
plications were observed in adult patients [3].
The data we collected do not differ from those of the above-
mentioned studies. The number of patients was found to
increase with age. The interval between chickenpox and herpes
zoster was 5.6 years on average. In a study conducted on the
popnlation of Iceland, on average slightly more than 8 years
passed from chickenpox to the appearance of herpes zoster, but
adolescents with herpes zoster aged up to 19 were also included.
In all of our patients, the course of the disease was extremely
mild and there were no complications. It is therefore disputable
whether treatment with acyclovir is justified, apart from excep-
tional cases (e.g. in severely immunocompromised children). In
the children from this study as well, herpes zoster was most often
located in the thoracic area and only in one child in the
ophthalmic area. In adnlts, however, thoracic herpes zoster is
found in only half of the cases and cranial herpes zoster in over
10% of patients [5].
In children whose mothers had chickenpox during preg-
nancy, herpes zoster may appear as early as the first year oflife. In
only one of86 children did the mother have chickenpox during
pregnancy, and herpes zoster appeared very soon after the first
year of life. The immune system of the fetus is undoubtedly
immature, which, in the opinion of some, is the reason for the
early appearance of the disease [2]. The correlation between
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chickenpox before the first year of age and herpes zoster in
children was not analyzed, because the number ofchildren with
chickenpox at the age ofless than 1 year was insufficient to form
a sample.
Even though herpes zoster is a disease of the elderly, it is not
all that rare in children; however, the course of the disease is
mainly mild and without sequelae.
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Cefditoren is a new expanded-spectrum orally administered
cephalosporin currently undergoing clinical trials in the USA
[1]. Its antimicrobial spectrum includes both Gram-positive and
Gram-negative species, but it is noteworthy for its particnlar
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Table 1 Distribution of MICs for six QC strains"
Broth microdilution MICs (mg(L)
Organism (ATCC No.)
Escherichia coli (25922)
Staphylococcus aureus (29213)
Streptococcus pneumoniae (49619)
H influenzae (49247)
H influenzae (49766)
No. of tests
594
600
500
300
499
0.004
45
0.008
424
0.016
28
0.03
279
2
0.06
245
5
"Number of times each MIC was reported; values in bold are within the proposed QC limits for each strain.
potency against the major respiratory pathogens Haemophilus
infiuenzae and Streptococcus pneumoniae [1,2]. In order to ensure
accurate in vitro susceptibility tests with this drug, quality
control (QC) parameters are necessary for the standard QC
organisms. In the course ofour in vitro studies ofcefditoren, we
have conducted a multilaboratory study to determine the QC
parameters for cefditoren when tested by the National Com-
mittee for Clinical Laboratory Standards (NCCLS) methods for
broth microdilution [3] and disk diffusion [5] susceptibility tests.
The design of these studies exceeded the minimum require-
ments of the NCCLS [4]. Ten North American medical centers
participated in each study. Each laboratory performed the broth
microdilution and disk diffusion tests as outlined by the NCCLS
[3,5]. Broth microdilution trays were prepared to contain serial
dilutions of cefditoren with concentrations ranging from 0.004
to 32 mg/L in each of six different lots of cation-adjusted
Mueller-Hinton broth (CAMHB) from four different manu-
facturers for testing non-fastidious strains, and five lots of
CAMHB with 3% lysed horse blood for Streptococcus pneumoniae,
five lots with Haemophilus Test Medium (HTM) supplements
for H. infiuenzae ATCC 49766, and three lots for H. infiuenzae
ATCC 49247. These media were freshly prepared and stored at
<;- 60°C until used (up to 14 days). Serial dilutions of
cefotaxime or cefuroxime were prepared in one lot of broth
as control drugs. Three lots of Mueller-Hinton agar (MBA)
from three different manufacturers were used for disk diffusion
tests, along with two lots of 5-J-lg cefditoren disks prepared by
two different manufacturers. The MHA was supplemented with
5% sheep blood or HTM supplements for testing S. pneumoniae
or H. infiuenzae. HTM agar was freshly prepared and used
within 14 days. Cefotaxime 30-J-lg disks or cefixime 5-J-lgdisks
served as controls. On each of 10 separate days, all participants
inoculated one microdilution tray and three different MBA agar
plates for each organism tested. This resulted in a total of 600
disk diffusion zone diameter measurements for each QC strain
tested, 600 MIC determinations for each non-fastidious QC
strain, 500 MIC determinations for the S. pneumoniae QC strain
and H. infiuenzae ATCC 49766, and 300 MIC determinations
for H. infiuenzae ATCC 49247. Whenever the control drug
results were outside the NCCLS range, the corresponding
Table 2 Distribution of zone diameters for six QC strains"
Disk diffusion zone diameters (mm)
Organism No. of
(ATCCNo.) tests 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37
EC 590 14 76 175 195 89 34 7
(25992)
SA 590 10 34 108 188 149 51 23 17 5
(25923)
SP 597 3 5 21 45 77 120 154 98 44 19 11
(49619)
HI 576 11 21 75 106 110 122 66 40 8 8 3 4 2
(49247)
"Number of times each zone diameter was reported; values in bold are within the proposed QC limits for each strain. EC,Escherichia coli; SA, Staphylococcus
aureus; SP,Streptococcus pneumoniae; HI, Haemophilus influenzae.
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Table 3 Recommended QC ranges for cefditoren" and percentage of results in range
Organism (ATCC No.)
Escherichiacoli (25922)
Staphylococcus aureus (29213)
Staphylococcus aureus (25923)
Streptococcus pneumoniae (49619)
Haemophilus influenzae (49247)
Haemophilus influenzae (49766)
MICs (mg(L)
Range
0.12-1.0
0.25-2.0
NA
0.016-0.12
0.06-0.25
0.004-0.016
% in range
100
100
100
100
99.6
Zone diameters (mm)
Range
22-28
NA
20-28
27-35
25-34
NR
% in range
100
98.3
98.7
98.3
a These QC ranges were approved by the NCClS in June, 1999. NA, not applicable; NR, no recommendations (results off-scale or zones too large).
cefditoren results were omitted from the calculations even
though these would not have influenced the cefditoren pro-
posed ranges. Colony counts were performed on the growth
control suspension on each test day to ensure appropriate
inoculum density.
The distribution of MICs and zone diameter results with
these control organisms are summarized in Tables 1 and 2.
There were no appreciable differences in these distributions
when the results were stratified by media lot or laboratories.
The QC organisms tested, the proposed ranges and the per-
centage of results falling within these ranges are summarized in
Table 3. A four-dilution MIC range was proposed for most
strains because the mode fell between two adjacent concentra-
tions that were tested. One laboratory also performed cefdi-
toren agar dilution tests with each QC strain on 15 separate
days, and all MIC results fell within these proposed ranges. The
MIC QC range for H. influenzae ATCC 49247 was approved by
the NCCLS in June 2000; all other QC ranges listed in Tables 1
and 2 for both disk diffusion and dilution tests were approved by
the NCCLS subcommittee on antimicrobial susceptibility tests
in June 1999.
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